Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|June 9, 2022

Johnson Matthey Health Rebrands as Veranova

Following the acquisition by Altaris Capital Partners, Johnson Matthey Health has rebranded as Veranova.

Veranova, a contract manufacturing and development organization focusing on APIs, announced its launch as an independent company on June 1, 2022. Formerly known as Johnson Matthey Health, Veranova has rebranded itself following its acquisition by Altaris Capital Partners.

According to a company press release, the new name originates from the Latin words ‘vērus’ meaning ‘true’ and ‘nŏvus’ meaning ‘new’, representing the reliability and innovative approach of the company respectively. Veranova currently holds over 425 active patents and over the course of the past century has helped develop more than 100 APIs, including the first platinum-based drugs for cancer treatment.

Veranova is headquartered in Wayne, PA, with manufacturing operations in West Deptford, NJ; Devens, MA; North Andover, MA; Annan, UK; and Edinburgh, UK. The company also has manufacturing and R&D centers in Cambridge, UK, and Yantai, China.

Source: Veranova


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.